SCHEMBL1627170

SCHEMBL1627170

O=C(NCCc1cccs1)c1ccc2[nH]c(-c3n[nH]c4ccsc34)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
LMNA P02545 1/20 0.48
CYP1A2 P05177 2/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
TAAR1 Q96RJ0 1/20 0.46
ITK Q08881 3/20 0.45
LCK P06239 2/20 0.45
TXK P42681 2/20 0.45
SYK P43405 2/20 0.45
PSMD14 O00487 1/20 0.44
STAMBP O95630 1/20 0.44
COPS5 Q92905 1/20 0.44
MAPK1 P28482 2/20 0.43
TTK P33981 1/20 0.43
MAPK3 P27361 1/20 0.43
DRD2 P14416 2/20 0.42
DRD3 P35462 2/20 0.42
BRD4 O60885 1/20 0.42
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1622884 0.93 ITK (0.50) NPC1RAB9ALMNACYP1A2SMN1; SMN2
SCHEMBL2903568 0.85 ITK (0.43) NPC1RAB9ALMNASMN1; SMN2ITK
SCHEMBL13869803 0.81 ITK (0.60) NPC1RAB9ASMN1; SMN2ITKLCK
SCHEMBL2898022 0.80 ITK (0.47) NPC1RAB9ALMNASMN1; SMN2ITK
SCHEMBL27645976 0.78 ITK (0.54) ITKLCKTXKSYKMAPK1
SCHEMBL14508645 0.78 CYP1A2 (0.47) NPC1RAB9ALMNACYP1A2SMN1; SMN2
SCHEMBL1620556 0.77 ITK (0.51) RAB9ASMN1; SMN2ITKLCKTXK
SCHEMBL1623118 0.77 ITK (0.51) NPC1RAB9ASMN1; SMN2ITKLCK
SCHEMBL1623956 0.76 ITK (0.58) ITKLCKTXKSYK
SCHEMBL1623119 0.76 ITK (0.47) NPC1RAB9ACYP1A2SMN1; SMN2ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682553-B1 THIENOPYRAZOLES AVENTIS PHARMA INC (US) 2010-05-19 EP claimed
US-20100056514-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2010-03-04 US claimed
US-7518000-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS, INC. (US) 2009-04-14 US claimed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US claimed
JP-2007505038-A 2007-03-08 JP claimed
EP-1682553-A1 THIENOPYRAZOLES Aventis Pharmaceuticals Inc. (US) 2006-07-26 EP claimed
WO-2005026175-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 WO claimed
US-7928231-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2011-04-19 US disclosed
US-7928231-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2011-04-19 US disclosed
US-7928231-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2011-04-19 US disclosed
EP-1682553-B1 THIENOPYRAZOLES AVENTIS PHARMA INC (US) 2010-05-19 EP disclosed
US-20100056514-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2010-03-04 US disclosed
US-20100056514-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2010-03-04 US disclosed
US-20100056514-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2010-03-04 US disclosed
US-7518000-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed
US-7518000-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed
US-7518000-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056514-A1 THIENOPYRAZOLES ITK, IL2, TYK2 NPC1 4488/4885RAB9A 3618/4885LMNA 4631/4885
US-20070254937-A1 Thienopyrazoles ITK, IL2, JAK2 NPC1 4164/4885RAB9A 3718/4885LMNA 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.